Goldman Sachs Reiterates Buy on Incyte (INCY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/9/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Atlassian results seen as 'game changer' for AI kills software worries
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Incyte to Present Diversified Development Portfolio and Opportunities for Accelerated Growth at 2018 Investor and Analyst Event
June 21, 2018 8:30 AM EDTFive late-stage oncology product candidates being developed in 15 different indications have the potential to significantly accelerate near-term revenue growth Pivotal REACH1 study of Jakafi® (ruxolitinib) in steroid-refractory acute GVHD met primary endpoint; sNDA submission expected in the third quarter of 2018 Development programs for PD-1 antagonist and JAK1, FGFR and PI3K inhibitors progressing as planned, with the first NDA submission for INCB54828 (FGFR) in cholangiocarcinoma expected in 2019 Inflammation/autoimmunity portfolio highlighted by success of randomized study of topical ruxolitinib in mild-to-moderate... More
Incyte Announces REACH1 Pivotal Trial Meets Primary Endpoint of Overall Response Rate for Ruxolitinib (Jakafi®) in Steroid-Refractory Acute Graft-Versus-Host Disease
June 21, 2018 7:00 AM EDTResults support planned sNDA submission in 2018
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq: INCY) today announced positive topline results from its ongoing pivotal Phase 2 REACH1 trial evaluating ruxolitinib (Jakafi®) in combination with corticosteroids for the treatment of patients with steroid-refractory acute graft-versus-host disease (GVHD). The study met its primary endpoint, demonstrating an overall response rate (ORR) of 55 percent (n=39/71) at Day 28. In addition, the best overall response rate (BORR), the number of patients achieving a response at any time point during the study, was 73 percent (n=52/71). The most common... More
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
June 20, 2018 7:00 AM EDTSix New Biotechnology Companies Added to the Index
LENEXA, Kan.--(BUSINESS WIRE)-- Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a stock index of top companies developing cancer immunotherapy treatments and discovering new ways to use the bodys immune system to fight cancer.
The Committee has added Arcus Biosciences... More
